Myeloma Active Clinical Trials

Numerous clinical trials are always active (ie, open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who have or are at risk of developing cancer. The buttons below depict the general research categories being investigated in ECOG-ACRIN clinical trials. To access information within a particular category, click on the relevant button. Upon clicking, the color of the button will change from grey to red, and a table will appear on screen. The table will display the study number, study description, lead investigator(s), accrual goal, and the date participating institutions started to open the trial. Please read the ECOG-ACRIN Disclaimer in its entirety before accessing this information.

Need More Information About a Particular Clinical Trial? Contact Us

To view educational materials, click on the links provided in the Educational Materials column. To send an email to the study chair, click on their name and a new email window will open.

Brain

Breast

Cancer Care Delivery Research

Cancer Control and Survivorship

Trials Currently Recruiting Participants - Myeloma Committee

STUDY	DESCRIPTION	ECOG-ACRIN STUDY CHAIR (STATISTICIAN)	ACCRUAL GOAL	DATE ACTIVATED	EDUCATIONAL MATERIALS
EAA172	A Phase I/II Study of Daratumumab, Bortezomib, Dexamethasone with or without Venetoclax in Relapsed/Refractory Multiple Myeloma with Assessment for t(11;14) Status Note: Enrollment suspended. This trial will re-open as soon as a protocol amendment is completed.	Michael A. Thompson, MD, PhD, Chair Murali Janakirum, MD, Co-Chair Sagar Lonial, MD, Co-Chair (Susanna Jacobus, ScM)	282	01/25/2019	EAA172 Resources
EAA173	Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)	Natalie S. Callander, MD, Chair Sagar Lonial, MD, Co-Chair (Susanna Jacobus, ScM)	288	04/30/2019	EAA173 Resources

STUDY DESCRIPTION ECOG-ACRIN STUDY CHAIR
(STATISTICIAN) ACCRUAL
GOAL DATE
ACTIVATED EDUCATIONAL MATERIALS

EAA172 A Phase I/II Study of Daratumumab, Bortezomib, Dexamethasone with or without Venetoclax in Relapsed/Refractory Multiple Myeloma with Assessment for t(11;14) Status

Note: Enrollment suspended. This trial will re-open as soon as a protocol amendment is completed. Michael A. Thompson, MD, PhD, Chair
Murali Janakirum, MD, Co-Chair
Sagar Lonial, MD, Co-Chair
(Susanna Jacobus, ScM) 282 01/25/2019 EAA172 Resources

EAA173 Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) Natalie S. Callander, MD, Chair
Sagar Lonial, MD, Co-Chair
(Susanna Jacobus, ScM) 288 04/30/2019 EAA173 Resources

Download